BMS-201038 (AEGR-733)

Phase 2Small molecule

AAegerion Pharmaceuticals, Inc.

BMS-201038 (AEGR-733) is one of 36 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypercholesterolemiaActive, not recruiting

HypercholesterolemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

130 competitors in Hypercholesterolemia

#DrugCompanyPhaseTrials

Lescol

Novartis

Phase 3

1 2

Micardis

Boehringer Ingelheim

Phase 3

1 3

Comparator: Statins

Merck & Co.

Phase 3

3 4

Comparator: Pbo

Merck & Co.

Phase 3

2 5

Evacetrapib

Eli Lilly

Phase 3

2 6

Kynamro

KKastle Therapeutics, LLC

Phase 3

1 7

Enlicitide

Merck & Co.

Phase 3

3 8

Anacetrapib

Merck & Co.

Phase 3

1 9

Lapaquistat Acetate

Takeda

Phase 3

9 10

Bococizumab

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypercholesterolemia1 trial

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

Completed·AAegerion Pharmaceuticals, Inc.·Phase 2·NCT00405067·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-201038 (AEGR-733). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-201038 (AEGR-733) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-201038 (AEGR-733). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aegerion Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAegerion Pharmaceuticals, Inc.

BMS-201038 (AEGR-733)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypercholesterolemia1 trial

References

Drug Info

Quick Facts

Related News